AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
Clinical trial NCT00396201 · COMPLETED
Trial details
- NCT number
- NCT00396201
- Sponsor
- Genzyme, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2004-11-01
- Primary completion
- 2006-10-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.